

Natasha A Jain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6529574/publications.pdf>

Version: 2024-02-01

35
papers

257
citations

1039880

9
h-index

940416

16
g-index

35
all docs

35
docs citations

35
times ranked

645
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical and financial burden of pre-emptive management of Cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. <i>Cytotherapy</i> , 2014, 16, 927-933.	0.3	56
2	Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues. <i>Leukemia</i> , 2014, 28, 1167-1170.	3.3	33
3	A multigene array for measurable residual disease detection in AML patients undergoing SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 642-651.	1.3	33
4	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. <i>Experimental Hematology</i> , 2014, 42, 83-89.	0.2	26
5	Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors. <i>Bone Marrow Transplantation</i> , 2016, 51, 1101-1106.	1.3	20
6	Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIg). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 134-137.	1.0	16
7	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 209-213.	2.0	13
8	Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors. <i>Bone Marrow Transplantation</i> , 2014, 49, 451-452.	1.3	9
9	A Rare Consequence of Chronic Graft Versus Host Disease - Peyronie's Disease. <i>Archives in Cancer Research</i> , 2015, 3, .	0.3	9
10	Immunotherapy in inoperable stage III non-small cell lung cancer: a review. <i>Drugs in Context</i> , 2019, 8, 1-6.	1.0	9
11	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 189-196.	1.3	7
12	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2016, 24, 815-822.	1.0	6
13	Radiation exposure from diagnostic procedures following allogeneic stem cell transplantation — How much is acceptable?. <i>Hematology</i> , 2014, 19, 275-279.	0.7	5
14	<p>Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11743-11749.	0.9	5
15	Clinical comorbidity predictive measures in ex vivo T-cell-depleted allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 1138-1140.	1.3	3
16	Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT). <i>Blood</i> , 2013, 122, 2124-2124.	0.6	3
17	Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors. <i>Clinical Hematology International</i> , 2020, 2, 109.	0.7	2
18	Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cell-Depleted Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 954-955.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Association of Comprehensive Lipoprotein Profiling with Coronary Artery Disease in Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. <i>Blood</i> , 2016, 128, 828-828.	0.6	1
20	Post-Transplant Pulmonary Function Abnormalities Nadir At Five Years and Then Fully Normalize by the Second Decade in Allogeneic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S151.	2.0	0
21	The Clinical and Financial Cost of Preemptive Management of CMV Disease – Implications for Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S128.	2.0	0
22	Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S268.	2.0	0
23	Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S276-S277.	2.0	0
24	Clinical and laboratory predictors impacting allogeneic peripheral blood stem cell mobilization. <i>Cytotherapy</i> , 2015, 17, S66.	0.3	0
25	Cardiac CT Imaging Is a Feasible Screening Strategy for Coronary Artery Disease (CAD) in Long Term Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S73.	2.0	0
26	Bone Mineral Density (BMD) Improves in Survivors in Their Second Decade Post-Allogeneic Stem Cell Transplantation and Is Influenced By Body Mass Index (BMI) and Age. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S171.	2.0	0
27	Clinical Risk Factor Modeling for Late Coronary Artery Disease – An NHLBI Allogeneic Stem Cell Transplant Survivorship Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S223-S224.	2.0	0
28	Premature coronary artery disease following allogeneic stem cell transplantation: an NHLBI Cohort Study. <i>Bone Marrow Transplantation</i> , 2019, 54, 320-322.	1.3	0
29	Post-Transplant Pulmonary Function Abnormalities Normalize in Survivors by the Second Decade After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 1967-1967.	0.6	0
30	Contrast Enhanced Cardiac CT Detects Coronary Artery Disease In 44% Of Asymptomatic Long-Term Adult Allogeneic Stem Cell Transplant Survivors. <i>Blood</i> , 2013, 122, 2080-2080.	0.6	0
31	A Novel Multi-Gene Array Allows Relapse Risk Stratification in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 667-667.	0.6	0
32	Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2550-2550.	0.6	0
33	Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct. <i>Blood</i> , 2015, 126, 3212-3212.	0.6	0
34	Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation. <i>Blood</i> , 2016, 128, 4596-4596.	0.6	0
35	Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14170-e14170.	0.8	0